Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Increase in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 99,400 shares, a growth of 196.7% from the February 29th total of 33,500 shares. Based on an average daily volume of 78,500 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.7% of the company’s stock are short sold.

Institutional Trading of Indaptus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new position in shares of Indaptus Therapeutics during the 4th quarter valued at about $29,000. Northern Trust Corp purchased a new position in shares of Indaptus Therapeutics during the 1st quarter valued at about $41,000. Renaissance Technologies LLC purchased a new position in shares of Indaptus Therapeutics during the 2nd quarter valued at about $51,000. State Street Corp purchased a new position in shares of Indaptus Therapeutics during the 1st quarter valued at about $78,000. Finally, Vanguard Group Inc. raised its stake in shares of Indaptus Therapeutics by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock valued at $451,000 after buying an additional 5,517 shares during the last quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Stock Down 11.1 %

Shares of INDP opened at $2.49 on Thursday. The stock has a 50-day moving average of $1.91 and a two-hundred day moving average of $2.17. Indaptus Therapeutics has a one year low of $1.56 and a one year high of $4.08.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.